Replies to post #18944 on Mymetics Corp (MYMX)

[Work Harder]

Ditto Happy 4th all

During the last quarter of 2019, the Company received an amount of E111 related to the Amendment 3 of the Research and Option to License Agreement dated September 3rd, 2019. This revenue is fully recognized as the deliverables for the Stallergenes-Anergis study were met and Anergis paid for an extension of the option to execute the LCA.

A nice amount of deliverables from Maciviva. I take that to mean compounds / proteins what have ya across all partners. Still waiting on an explanation on that. Beyond Upperton, what products do the others have.

It's interesting how Mr K defines deliverables in the filings including license revs

Be safe folks